Phathom Pharmaceuticals, Inc. Beginning Cash

Beginning Cash of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Beginning Cash growth rates and interactive chart.


Highlights and Quick Summary

  • Beginning Cash for the quarter ending June 29, 2021 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Beginning Cash decreased by NaN%
  • Annual Beginning Cash for 2020 was $244 Million (a 27632.08% increase from previous year)
  • Twelve month Beginning Cash ending June 29, 2021 was $287 Million (a 0.0% decrease compared to previous quarter)
  • Twelve month trailing Beginning Cash increased by 17.94% year-over-year
Trailing Beginning Cash for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$287 Million $287 Million $244 Million $244 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Beginning Cash of Phathom Pharmaceuticals, Inc.

Most recent Beginning Cashof PHAT including historical data for past 10 years.

Interactive Chart of Beginning Cash of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Beginning Cash for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.0 $287.5
2020 $0.0 $0.0 $0.0 $243.77 $243.77
2019 $0.0 $0.0 $0.0 $0.88 $0.88
2018 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.